NASDAQ:HURA

TuHURA Biosciences Q1 2026 Earnings Results & Report

TuHURA Biosciences logo
$1.41 +0.01 (+0.71%)
As of 01:26 PM Eastern
This is a fair market value price provided by Massive. Learn more.

TuHURA Biosciences missed analyst earnings expectations in its Q1 2026 results, released May 15, 2026. The company reported EPS of -$0.13 versus the -$0.12 consensus estimate.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

TuHURA Biosciences EPS Results

Actual EPS
-$0.13
Consensus EPS
-$0.12
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

TuHURA Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

TuHURA Biosciences Q1 2026 Earnings FAQ

TuHURA Biosciences (NASDAQ:HURA) reported earnings of -$0.13 per share for Q1 2026, missing the consensus estimate of -$0.12. The report was announced on Friday, May 15, 2026.

TuHURA Biosciences Earnings Headlines

Your Social Security check is scheduled for a 22% cut
The U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt death spiral. Interest payments alone now top a trillion dollars a year. The Social Security trust fund is projected to run dry by 2032, which could trigger an automatic 22% cut to benefits. Between 2020 and 2022, the Fed expanded the money supply by 41%. A free 27 page report breaks down these numbers in plain English, including what central banks have been doing with gold.tc pixel
See More TuHURA Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like TuHURA Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TuHURA Biosciences and other key companies, straight to your email.

About TuHURA Biosciences

TuHURA Biosciences (NASDAQ:HURA) is a clinical-stage biotechnology company developing immunotherapies for cancer. Its research focuses on treatments intended to stimulate the immune system and address mechanisms that allow tumors to evade immune attack.

The company’s pipeline includes IFx-2.0, an investigational intratumoral immunotherapy being studied for use with checkpoint inhibitors, as well as antibody programs targeting immune-regulating pathways. TuHURA has no marketed products, and its candidates remain in development.

TuHURA became a publicly traded company following its 2024 merger with Kintara Therapeutics. The company is based in Tampa, Florida, and is led by President and Chief Executive Officer James Bianco.

View TuHURA Biosciences Profile